Abstract:Heart failure is one of the most important problems in public health. Although big advances had been reached in treatment, the prognosis of advanced heart failure is still reserved and the heart transplant is the main therapy for this stage of disease. Allograft rejection is responsible for mortality in transplantation patients and the diagnosis of this complication is made through an invasive diagnostic method – the cardiac biopsy. The inflammatory response has been described in cardiovascular disease and in allograft rejection process. The objective of this study is to evaluate levels of sCD40, sCD40L and s4-1BB (inflammatory biomarkers) in advanced heart failure and post heart transplant with allograft rejection comparing to normal individuals and post heart transplant patients with no allograft rejection. The study population comprised 38 patients undergoing heart transplant in our center. Fifteen patients had biomarkers dosed before heart transplant and twenty three patients had dosed just after procedure. In this group, six patients were enrolled in the study for clinical suspicion of rejection. Nineteen health persons composed the control group with age between 18 and 49 years. Plasma dosage of sCD40, sCD40L e s4-1BB was made by enzyme linked immunosorbentassay (ELISA). Mann-Whitney test, Wilcoxon and t test were used to analyse dates. Statistical analysis used GraphPad®Prism6 and the value p< 0,05 was considered statistical significant. Allograft rejection occurred in 6,26% of studied patients. There was no statistical difference in age, sex, comorbities as hypertension, diabetes or etiology of cardiomyopathy. Serum levels of sCD40, sCD40L e s4-1BB were higher in patients with advanced heart failure comparing to controls (p< 0,0001). There was no difference in these levels of sCD40 (p = 0,74) e sCD40L (p = 0,44) between groups with and without rejection. Levels of s4-1BB were significantly lower in patients with allograft rejection (p= 0,02). The sCD40/PCR and s4-1BB/PCR indexs were significantly higher in the group of patients with allograft rejection (p =0,02 e p= 0,0001). We concluded that sCD40, sCD40L e s4-1BB are biomarkers of severe heart failure. The serum level of s4-1BB could be a potential biomarker of allograft rejection and the association of sCD40 and s4-1BB with PCR could be a better strategy to this.

Serum levels of soluble interleukin‐2 receptor (sIL‐2R) fail to correlate with the occurrence and degree of rejection in heart transplant patients

Long‐term soluble interleukin‐2 receptor level of heart transplant recipients

Serum levels of soluble interleukin‐2 receptor, C‐reactive protein, neopterin, myoglobin and light chains of cardiac myosin fail to correlate with the occurrence of rejection in long‐term renal and heart transplant patients

Elevated serum IL-21 levels are associated with stable immune status in kidney transplant recipients and a mouse model of kidney transplantation

Acute rejection episodic outcomes resulted from pre-transplant serum level of the soluble CD30 in kidney transplant recipients

Clinical Significance Of Serum And Urine Soluble Interleukin 2 Receptor, C-Reactive Protein, Cystatin C, and Serum and Urine Creatinine in Renal Transplant Patients

Soluble interleukin‐2 receptor monitoring during bacterial and viral infections in liver transplant recipients: A comparative evaluation 1

leukin-15 (IL-15) production during acute rejection following heart transplantation in mice. Inbred male Balb/c (H-2d) and C57BL/6 (H-2b) mice were used to establish a heterotopic intra-abdominal cardiac transplantation model. The mice were divided in four groups: syngeneic control, allogeneic acute

High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome

Evaluation of serum levels of sCD40, sCD40L and s4-1BB in advanced heart failure and after heart transplant

Interleukin-2 Receptor Antagonist Compared With Antithymocyte Globulin Induction Therapy In Kidney Transplantation From Donors After Cardiac Death

Serum Level of Soluble Fibrinogen-Like Protein 2 in Renal Allograft Recipients with Acute Rejection: a Preliminary Study.

Low Dose Interleukin-2 Induces Exosomes with Tolerance Markers (PDL1, CD73) and Significantly Delays Development of Chronic Rejection Following Murine Heterotopic Cardiac Transplantation

Levels of tumor necrosis factor (TNF) in sera of renal allograft recipients

IL-15 is Decreased Upon CsA and FK506 Treatment of Acute Rejection Following Heart Transplantation in Mice.

Interleukin 6 and interleukin 17A serum levels and gene- polymorphisms in the development of early allograft rejection in living donor liver transplant recipients

Study on the Inspection and Significance of Serum Soluble Interleukin-2 Receptor and Interleukin-6 Level in Bile after Liver Transplantation

Diagnosing Acute Cellular Rejection after Paediatric Liver Transplantation-Is There Room for Interleukin Profiles?

Reduced levels of both circulating CD4+ CD25+ CD127(low/neg) and CD4+ CD8(neg) invariant natural killer regulatory T cells in stable heart transplant recipients.

[The Level of IL-2 and IL-6 in Stimulated Peripheral Lymphocyte Supernatants of Kidney Transplant Recipients Can Predict Acute Renal Allograft Rejection].

The Relations Between Interleukin-2, 10 and Transplantation Tolerance to Rat Cardiac Allografts Induced by Intrathymic Inoculation